Company intelligence / Profile preview
Medikine, Inc.
Menlo Park, California, United Statesmedikine.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Medikine’s lead candidate MDK‑703, an extended half-life IL‑7 mimetic Fc-fusion protein discovered using the PEPTIKINE™ platform, is in a Phase 1 trial in healthy volunteers. Preclinical data show activity on T cell memory populations and avoidance of neutralizing antibodies to native IL‑7. Additional programs are at preclinical or discontinued stages.
- Therapeutic areas
- OncologyImmunologyInfectious DiseasesHematology
- Modalities
- Synthetic peptides (PEPTIKINES™)Fc-fusion proteinsAntibody fusion proteins
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical partnerships publicly disclosed as of latest available information. Company intends to seek partnerships to expand clinical-stage opportunities.
Beyond the preview
Go deeper on Medikine, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medikine, Inc..